ArticleEmerging infectious diseases2024
Emergence of Extensively Drug-Resistant Neisseria gonorrhoeae, France, 2023.
Article in Emerging infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Article
- Rise ofAntimicrobial agents and chemotherapy · 2026Article
- Rapid expansion of penA allele 60.001-containing endemic ceftriaxone-resistant gonococcal ST8123 lineage in Hangzhou, China.Infection · 2026Article
- Plasmids inClinical microbiology reviews · 2026Review
- Extensively drug-resistant (XDR)Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- [Superbugs Neisseria gonorrhoeae und Mycoplasma genitalium : Therapeutic challenges driven by antimicrobial resistance].Dermatologie (Heidelberg, Germany) · 2026Review
- Evolution and rise of antimicrobial resistance in key public health bacteria within and across the One Health sectors.Future microbiology · 2026Review
- Thiofrenomycins, new kalafungin-type pyranonaphthoquinone skeleton with sulfide linkage from Streptomyces sp. MM863L-181F9.The Journal of antibiotics · 2026Article
- A Review of Doxycycline Post-Exposure Prophylaxis and Its Implications for Antimicrobial Resistance and the Human Microbiome.Infectious diseases and therapy · 2026Review
- Whole-genome characterization of seven multidrug-resistantFrontiers in microbiology · 2026Article
- Investigation of ceftriaxone-resistantSexually transmitted infections · 2025Article
- Expansion ofThe New England journal of medicine · 2025Article
- Antimicrobial resistance inThe Lancet regional health. Europe · 2025Article
- Extensively Drug-Resistant Neisseria gonorrhoeae Strain, Canada.Emerging infectious diseases · 2025Article
- Origin, evolution, and success of pbla, the gonococcal beta-lactamase plasmid, and implications for public health.PLoS pathogens · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since 2022, Europe has had 4 cases of extensively drug-resistant Neisseria gonorrhoeae, sequence type 16406, that is resistant to ceftriaxone and highly resistant to azithromycin. We report 2 new cases from France in 2023 involving strains genetically related to the 4 cases from Europe as well as isolates from Cambodia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.